Hypertriglyceridemia is a type of dyslipidemia characterized by high triglyceride levels in the blood and increases the risk of cardiovascular disease. Conventional management includes antilipidemic medications such as statins, lowering LDL and triglyceride levels as well as raising HDL levels. However, the treatment may be stratified using omega-3 fatty acid supplements such as eicosatetraenoic acid (EPA) and docosahexaenoic acid (DHA), aka fish oil derivatives. Studies have shown that fish oil supplements reduce risk of cardiovascular diseases; however, the underlying mechanism and the extent of reduction in CVD needs more clarification. Our paper aims to review the clinical trials and observational studies in the current literature, investigating the use of fish oil and its benefits on cardiovascular system as well as the proposed underlying mechanism.
Fish Oil Derivatives in Hypertriglyceridemia: Mechanism and Cardiovascular Prevention: What do studies say?
M. Erbay,Nicole Norma Gamarra,Parth Patel,H. Ozkan,A. Wilson,Suvam Banerjee,Aydan Babazade,V. Londoño,Aayushi Sood,Rahul Gupta
Published 2023 in Current problems in cardiology
ABSTRACT
PUBLICATION RECORD
- Publication year
2023
- Venue
Current problems in cardiology
- Publication date
2023-08-01
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-77 of 77 references · Page 1 of 1
CITED BY
Showing 1-4 of 4 citing papers · Page 1 of 1